References
- Ahmad, F. B., Rossen, L. M., & Sutton, P. (2021, September 7). Provisional drug overdose data. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
- Assistant Secretary for Public Affairs (ASPA). (2020, April 22). Telehealth: Delivering care safely during COVID-19. HHS.Gov. https://www.hhs.gov/coronavirus/telehealth/index.html
- Barnett, M. L., & Huskamp, H. A. (2020). Telemedicine for mental health in the United States: Making progress, still a long way to go. Psychiatric Services (Washington, D.C.), 71(2), 197–198. https://doi.org/https://doi.org/10.1176/appi.ps.201900555
- Busch, A. B., Sugarman, D. E., Horvitz, L. E., & Greenfield, S. F. (2021). Telemedicine for treating mental health and substance use disorders: Reflections since the pandemic. Neuropsychopharmacology, 46(6), 1068–1070. https://doi.org/https://doi.org/10.1038/s41386-021-00960-4
- Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019). Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment, 104, 148–157. https://doi.org/https://doi.org/10.1016/j.jsat.2019.07.005
- Czeisler, M. É., Lane, R. I., Petrosky, E., Wiley, J. F., Christensen, A., Njai, R., Weaver, M. D., Robbins, R., Facer-Childs, E. R., Barger, L. K., Czeisler, C. A., Howard, M. E., & Rajaratnam, S. M. (2020). Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24–30, 2020. MMWR. Morbidity and Mortality Weekly Report, 69(32), 1049–1057. https://doi.org/https://doi.org/10.15585/mmwr.mm6932a1
- Dale, V., Coulton, S., Godfrey, C., Copello, A., Hodgson, R., Heather, N., Orford, J., Raistrick, D., Slegg, G., & Tober, G, UKATT Research Team. (2011). Exploring treatment attendance and its relationship to outcome in a randomized controlled trial of treatment for alcohol problems: Secondary analysis of the UK Alcohol Treatment Trial (UKATT). Alcohol and Alcoholism (Oxford, Oxfordshire), 46(5), 592–599. https://doi.org/https://doi.org/10.1093/alcalc/agr079
- Davis, C. S., & Samuels, E. A. (2020a). Opioid policy changes during the COVID-19 pandemic—And beyond. Journal of Addiction Medicine, 14(4), e4–e5. https://doi.org/https://doi.org/10.1097/ADM.0000000000000679
- Davis, C. S., & Samuels, E. A. (2020b). Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. International Journal of Drug Policy, 93, 102905. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.102905
- Eibl, J. K., Gauthier, G., Pellegrini, D., Daiter, J., Varenbut, M., Hogenbirk, J. C., & Marsh, D. C. (2017). The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug and Alcohol Dependence, 176, 133–138. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2017.01.048
- Frueh, B. C., Henderson, S., & Myrick, H. (2005). Telehealth service delivery for persons with alcoholism. Journal of Telemedicine and Telecare, 11(7), 4.
- Hatch-Maillette, M., Wells, E. A., Doyle, S. R., Brigham, G. S., Daley, D., DiCenzo, J., Donovan, D., Garrett, S., Horigian, V. E., Jenkins, L., Killeen, T., Owens, M., & Perl, H. I. (2016). Predictors of 12-step attendance and participation for individuals with stimulant use disorders. Journal of Substance Abuse Treatment, 68, 74–82. https://doi.org/https://doi.org/10.1016/j.jsat.2016.06.007
- Hulsey, J., Mellis, A., & Kelly, B. (2020). COVID-19 pandemic impact on patients, families & individuals in recovery from a SUD. https://www.addictionpolicy.org/post/covid-19-pandemic-impact-on-patients-families-individuals-in-recovery-fromsubstance-use-disorder
- King, V. L., Brooner, R. K., Peirce, J. M., Kolodner, K., & Kidorf, M. S. (2014). A randomized trial of web-based videoconferencing for substance abuse counseling. Journal of Substance Abuse Treatment, 46(1), 36–42. https://doi.org/https://doi.org/10.1016/j.jsat.2013.08.009
- Lin, L., Casteel, D., Shigekawa, E., Weyrich, M. S., Roby, D. H., & McMenamin, S. B. (2019). Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. Journal of Substance Abuse Treatment, 101, 38–49. https://doi.org/https://doi.org/10.1016/j.jsat.2019.03.007
- Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data
- Mallet, J., Dubertret, C., & Le Strat, Y. (2021). Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 106, 110070. https://doi.org/https://doi.org/10.1016/j.pnpbp.2020.110070
- Milward, J., Lynskey, M., & Strang, J. (2014). Solving the problem of non-attendance in substance abuse services. Drug and Alcohol Review, 33(6), 625–636. https://doi.org/https://doi.org/10.1111/dar.12194
- New York State Office of Addiction Services and Supports. (n.d.). Continuing COVID regulatory flexibility. Retrieved July 2, 2021, from https://oasas.ny.gov/system/files/documents/2021/06/continuing_covid_regulatory_flexibility.pdf
- New York State Office of Addiction Services and Supports (2019, December). Telepractice standards for OASAS designated providers. New York State Office of Addiction Services and Supports.
- NIDA (2020, June 15). Death. National Institute on Drug Abuse. https://www.drugabuse.gov/drug-topics/health-consequences-drug-misuse/death
- Park‑Lee, E., Lipari, R. N., & Hedden, S. L. (2017, September). Receipt of services for substance use and mental health issues among adults: Results from the 2016 National Survey on Drug Use and Health | CBHSQ data. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/receipt-services-substance-use-and-mental-health-issues-among-adults-results-2016-national
- Samuels, E. A., Clark, S. A., Wunsch, C., Jordison Keeler, L. A., Reddy, N., Vanjani, R., & Wightman, R. S. (2020). Innovation during COVID-19: Improving addiction treatment access. Journal of Addiction Medicine, 14(4), e8–e9. https://doi.org/https://doi.org/10.1097/ADM.0000000000000685
- Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ (Clinical Research Ed.), 357, j1550. https://doi.org/https://doi.org/10.1136/bmj.j1550
- Tarp, K., Bojesen, A. B., Mejldal, A., & Nielsen, A. S. (2017). Effectiveness of optional videoconferencing-based treatment of alcohol use disorders: Randomized controlled trial. JMIR Mental Health, 4(3), e38. https://doi.org/https://doi.org/10.2196/mental.6713
- United Sates Department of Justice. (n.d.). Title 21 United States code controlled substances act subchapter I - control and enforcement. Section 802. U.S. Department of Justice Drug Enforcement Administration. Retrieved May 12, 2021, from https://www.deadiversion.usdoj.gov/21cfr/21usc/802.htm
- Uscher-Pines, L., Sousa, J., Raja, P., Mehrotra, A., Barnett, M., & Huskamp, H. A. (2020). Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. Journal of Substance Abuse Treatment, 118, 108124. https://doi.org/https://doi.org/10.1016/j.jsat.2020.108124
- Velázquez, P. P., Gupta, G., Gupte, G., & Venter, J. (2020). Rapid implementation of telepsychiatry in a safety-net health system during COVID-19 using lean. NEJM Catalyst Innovations in Care Delivery, 3.